These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25941268)

  • 1. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
    Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
    Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
    Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
    Yao Y; Toshimoto K; Kim SJ; Yoshikado T; Sugiyama Y
    Drug Metab Dispos; 2018 Jul; 46(7):924-933. PubMed ID: 29712725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
    Shitara Y; Hirano M; Sato H; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
    Hinton LK; Galetin A; Houston JB
    Pharm Res; 2008 May; 25(5):1063-74. PubMed ID: 17901929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
    Tornio A; Neuvonen PJ; Niemi M; Backman JT
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Kimoto E; Li R; Scialis RJ; Lai Y; Varma MV
    Mol Pharm; 2015 Nov; 12(11):3943-52. PubMed ID: 26378985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
    Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2012 May; 91(5):846-55. PubMed ID: 22472994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
    Noé J; Portmann R; Brun ME; Funk C
    Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
    Iga K; Kiriyama A
    Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
    Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2011 Oct; 39(10):1977-86. PubMed ID: 21778352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
    Varma MV; Kimoto E; Scialis R; Bi Y; Lin J; Eng H; Kalgutkar AS; El-Kattan AF; Rodrigues AD; Tremaine LM
    Clin Pharmacol Ther; 2017 Mar; 101(3):406-415. PubMed ID: 27648490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
    Sharma P; Holmes VE; Elsby R; Lambert C; Surry D
    Xenobiotica; 2010 Jan; 40(1):24-37. PubMed ID: 19919292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
    Wang Q; Zheng M; Leil T
    CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.